Pharmacological management of diabetic dyslipidemia

References

• Rajalakshmi R, Prathiba V, Mohan V. Does tight control of systemic factors help in the management of diabetic retinopathy? Indian J Ophthalmol. 2016;64:62–68.
   PubMed Web of Science ®Google Scholar
• Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–78.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–2381.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696.
   PubMed Web of Science ®Google Scholar
• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1–10.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Lundman P, Da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011;28:1343–1351.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 1996;45(Suppl 3):S27–S30.
   PubMed Web of Science ®Google Scholar
• Jaiswal M, Schinske A, Pop-Busui R. Lipids and lipid management in diabetes. Best Pract Res Clin Endocrinol Metab. 2014;28:325–338.
   PubMed Web of Science ®Google Scholar
• Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011;97:350–356.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–1639.
   PubMed Web of Science ®Google Scholar
• Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733–749.
   PubMed Web of Science ®Google Scholar
• Watts GF, Playford DA. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis. 1998;141:17–30.
   PubMed Web of Science ®Google Scholar
• Stahlman M, Fagerberg B, Adiels M, et al. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles. Biochim Biophys Acta. 2013;1831:1609–1617.
   PubMed Web of Science ®Google Scholar
• Le Goff W, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther. 2004;101:17–38.
   PubMed Web of Science ®Google Scholar
• Gazi I, Tsimihodimos V, Filippatos T, et al. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism. 2006;55:885–891.
   PubMed Web of Science ®Google Scholar
• Gazi I, Tsimihodimos V, Filippatos TD, et al. LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis. 2006;5:8.
   PubMed Web of Science ®Google Scholar
• Lagos KG, Filippatos TD, Tsimihodimos V, et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids. 2009;44:9–16.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Rizos EC, Tsimihodimos V, et al. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A(2) in subjects with prediabetes. Lipids. 2013;48:547–555.
   PubMed Web of Science ®Google Scholar
• Yazdanyar A, Yeang C, Jiang XC. Role of phospholipid transfer protein in high-density lipoprotein- mediated reverse cholesterol transport. Curr Atheroscler Rep. 2011;13:242–248.
   PubMed Web of Science ®Google Scholar
• Persegol L, Verges B, Foissac M, et al. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2006;49:1380–1386.
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Wierzbicki AS, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370–378.
   PubMed Web of Science ®Google Scholar
• Annema W, Von Eckardstein A. Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. Transl Res. 2016;173:30–57.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Gazi I, Filippatos T, et al. Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis. 2010;208:506–511.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. High density lipoprotein and cardiovascular diseases. World J Cardiol. 2013;5:210–214.
   PubMedGoogle Scholar
• La Belle M, Krauss RM. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass patterns. J Lipid Res. 1990;31:1577–1588.
   PubMed Web of Science ®Google Scholar
• Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363–1379.
   PubMed Web of Science ®Google Scholar
• Tribble DL, Holl LG, Wood PD, et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992;93:189–199.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. Qjm. 2006;99:1–14.
   PubMed Web of Science ®Google Scholar
• Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007;7:53–72.
   PubMed Web of Science ®Google Scholar
• Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51:2264–2273.
   PubMed Web of Science ®Google Scholar
• Gazi IF, Filippatos TD, Tsimihodimos V, et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids. 2006;41:647–654.
   PubMed Web of Science ®Google Scholar
• Gazi IF, Milionis HJ, Filippatos TD, et al. Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. Diabetes Metab Res Rev. 2008;24:223–230.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;2014(63):2889–2934.
   Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. acc expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2016;2016(68):92–125.
   Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl):S1–S99.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016. DOI:10.1093/eurheartj/ehw272
   Web of Science ®Google Scholar
• Wang ZH, Liu XL, Zhong M, et al. Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol. 2010;50:311–319.
   PubMed Web of Science ®Google Scholar
• Murrow JR, Sher S, Ali S, et al. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol. 2012;6:42–49.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des. 2009;15:479–489.
   PubMed Web of Science ®Google Scholar
• Krysiak R, Gdula-Dymek A, Bachowski R, et al. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care. 2010;33:2266–2270.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Mikhailidis DP. Statins and heart failure. Angiology. 2008;59:58S–61S.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Tsimihodimos V, Filippatos TD, et al. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids. 2011;46:521–528.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Tsimihodimos V, Filippatos TD, et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother. 2011;12:2605–2611.
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in. 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–571.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335:1001–1009.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREEk Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220–228.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama. 2001;285:1711–1718.
   PubMed Web of Science ®Google Scholar
• Donner-Banzhoff N, Sonnichsen A. Statins and primary prevention of cardiovascular events. Bmj. 2008;337:a2576.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–1781.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453–463.
   PubMed Web of Science ®Google Scholar
• Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther. 2009;31:236–244.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. Qjm. 2011;104:109–124.
   PubMed Web of Science ®Google Scholar
• Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999;159:1793–1802.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006;151:273–281.
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016.
   PubMed Web of Science ®Google Scholar
• Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–1485.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. Jama. 2011;305:2556–2564.
   PubMed Web of Science ®Google Scholar
• Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;CD004816. doi: 10.1002/14651858.
   Google Scholar
• Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Bmj. 2006;332:1115–1124.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007;195:7–16.
   PubMed Web of Science ®Google Scholar
• Leung A, Schaefer EW, Tempelhof MW, et al. Emphasizing statin safety in the hospitalized patient: a review. Am J Med. 2012;125:845–853.
   PubMed Web of Science ®Google Scholar
• Stein EA, Vidt DG, Shepherd J, et al. Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis. 2012;221:471–477.
   PubMed Web of Science ®Google Scholar
• Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. Cmaj. 2008;178:576–584.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Clark JA, Glass LM, et al. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97:32C–43C.
   PubMed Web of Science ®Google Scholar
• Floyd JS, Heckbert SR, Weiss NS, et al. Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. Jama. 2012;307:1580–1582.
   PubMed Web of Science ®Google Scholar
• Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400–409.
   PubMed Web of Science ®Google Scholar
• Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf. 2012;11:439–444.
   PubMed Web of Science ®Google Scholar
• Kei AA, Filippatos TD, Elisaf MS. The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opin Drug Saf. 2016;15:559–569.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Liamis GL, Milionis HJ, et al. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol. 2010;8:612–631.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–742.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Pitavastatin and carbohydrate metabolism: what is the evidence? Expert Rev Clin Pharmacol. 2016;9:955–960.
   PubMed Web of Science ®Google Scholar
• Livingstone SJ, Looker HC, Akbar T, et al. Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS). Diabetologia. 2016;59:299–306.
   PubMed Web of Science ®Google Scholar
• Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014;57:2444–2452.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des. 2009;15:490–516.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23:2009–2026.
   PubMed Web of Science ®Google Scholar
• Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–261.
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007;23:1169–1176.
   PubMed Web of Science ®Google Scholar
• Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106–107.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69–76.
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207–213.
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–2134.
   PubMed Web of Science ®Google Scholar
• Ohbu-Murayama K, Adachi H, Hirai Y, et al. Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome. J Diabetes Investig. 2015;6:325–333.
   PubMed Web of Science ®Google Scholar
• Chang E, Kim L, Choi JM, et al. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism. 2015;64:633–641.
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol. 2010;633:62–70.
   PubMed Web of Science ®Google Scholar
• Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother. 2008;9:3151–3158.
   PubMed Web of Science ®Google Scholar
• Nakou ES, Filippatos TD, Agouridis AP, et al. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids. 2010;45:445–450.
   PubMed Web of Science ®Google Scholar
• Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008;24:1919–1929.
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Takamura T, Honda M, et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 2014;57:878–890.
   PubMed Web of Science ®Google Scholar
• Derdemezis C, Filippatos T, Tselepis A, et al. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother. 2008;9:1829–1837.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Statin-ezetimibe combination therapy in diabetic individuals. Angiology. 2016;67:507–509.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Effects of ezetimibe/simvastatin combination on metabolic parameters. Int J Cardiol. 2016;202:273–274.
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Moutzouri E, et al. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin. 2011;27:685–692.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Elisaf MS, Mikhailidis DP. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. J Cardiovasc Pharmacol Ther. 2012;17:427; author reply 8.
   PubMed Web of Science ®Google Scholar
• Moutzouri E, Liberopoulos EN, Florentin M, et al. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J Cardiovasc Pharmacol Ther. 2013;18:13–18.
   PubMed Web of Science ®Google Scholar
• Moutzouri E, Liberopoulos EN, Tellis CC, et al. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 2013;231:8–14.
   PubMed Web of Science ®Google Scholar
• Moutzouri E, Tellis CC, Rousouli K, et al. Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis. 2012;225:381–387.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Filippatos TD, Tsimihodimos V, et al. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther. 2011;9:355–366.
   PubMedGoogle Scholar
• Agouridis AP, Filippatos TD, Katsiki N. Current lipid-modifying agents. Expert Opin Pharmacother. 2015;16:1117–1118.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol. 2011;3:265–267.
   PubMedGoogle Scholar
• Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a statin after acute coronary syndromes. N Engl J Med. 2015;373:1476–1477.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Are lower levels of LDL-cholesterol really better? Looking at the results of IMPROVE-IT: opinions of three experts - III. Hellenic J Cardiol. 2015;56:7–9.
   PubMed Web of Science ®Google Scholar
• Ip CK, Jin DM, Gao JJ, et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. Int J Cardiol. 2015;191:138–148.
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract. 2008;62:88–96.
   PubMed Web of Science ®Google Scholar
• Barkas F, Elisaf M, Liberopoulos E, et al. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol. 2016;10:306–313.
   PubMed Web of Science ®Google Scholar
• Blazing M Incidence of new-onset diabetes in the IMPROVE-IT trial: does adding ezetimibe to simvastatin increase risk compared to simvastatin alone? Presented at: European Society of Cardiology Congress; Sep 1, 2015; London, England. https://www.acc.org/latest-in-cardiology/articles/2015/11/20/14/20/incidence-of-new-onset-diabetes-in-the-improve-it-trial?w_nav=Tab.
   Google Scholar
• Nozue T, Hattori H, Ogawa K, et al. Effects of statin therapy on plasma proprotein convertase subtilisin/kexin type 9 and sortilin levels in statin-naive patients with coronary artery disease. J Atheroscler Thromb. 2016;23:848–856.
   PubMed Web of Science ®Google Scholar
• Saito I, Azuma K, Kakikawa T, et al. A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis. 2015;14:40.
   PubMed Web of Science ®Google Scholar
• Ichimori S, Shimoda S, Goto R, et al. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3:179–184.
   PubMed Web of Science ®Google Scholar
• Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs. 2008;17:1599–1614.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Miltiadous G, Daskalopoulou SS, et al. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol. 2005;3:87–98.
   PubMedGoogle Scholar
• Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr Med Res Opin. 2000;16:21–32.
   PubMed Web of Science ®Google Scholar
• Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002;18:269–276.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin. 2005;21:1997–2006.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Georgoula M, et al. Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J Med Sci Res. 2007;2:9–10.
   Google Scholar
• Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007;193:428–437.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Liberopoulos EN, Kostapanos M, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab. 2008;10:476–483.
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother. 2008;9:2741–2750.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des. 2010;16:3401–3416.
   PubMed Web of Science ®Google Scholar
• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–910.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–1884.
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492–498.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12:1945–1958.
   PubMed Web of Science ®Google Scholar
• Filippatos TD. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovasc Drugs Ther. 2012;26:245–255.
   PubMed Web of Science ®Google Scholar
• Jones PH, Cusi K, Davidson MH, et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010;10:73–84.
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Bucci A, Di Giacomo S, et al. Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. Clin Drug Investig. 2004;24:465–477.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin. 2009;25:1973–1983.
   PubMed Web of Science ®Google Scholar
• Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol. 2011;107(1010–8):e1.
   PubMed Web of Science ®Google Scholar
• Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009;157:195–203.
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006;48:396–401.
   PubMed Web of Science ®Google Scholar
• May HT, Anderson JL, Pearson RR, et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined lipid Therapy Regimen study). Am J Cardiol. 2008;101:486–489.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198–1202.
   PubMed Web of Science ®Google Scholar
• Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract. 2004;64:137–151.
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009;204:208–215.
   PubMed Web of Science ®Google Scholar
• Roth EM, Rosenson RS, Carlson DM, et al. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovasc Drugs Ther. 2010;24:421–428.
   PubMed Web of Science ®Google Scholar
• Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Am J Cardiovasc Drugs. 2010;10:175–186.
   PubMed Web of Science ®Google Scholar
• Farnier M, Steinmetz A, Retterstol K, et al. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clin Ther. 2011;33:1–12.
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AE, Bertone G, et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther. 2004;26:1599–1607.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–468.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:37–45.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363:692–694.
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165:1154–1160.
   PubMed Web of Science ®Google Scholar
• Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21–27.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–418.
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–1245.
   PubMed Web of Science ®Google Scholar
• Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493–498.
   PubMed Web of Science ®Google Scholar
• Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–244.
   PubMed Web of Science ®Google Scholar
• Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015;19:1–12.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Bairaktari E, Elisaf M. Fibrate-induced increase in serum urea and creatinine levels. Nephrol Dial Transplant. 2002;17:682; author reply.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Miltiadous G, Bairaktari E, et al. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol. 2002;57:407–408.
   PubMed Web of Science ®Google Scholar
• Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92:536–541.
   PubMed Web of Science ®Google Scholar
• Forsblom C, Hiukka A, Leinonen ES, et al. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care. 2010;33:215–220.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. Eur J Clin Invest. 2013;43:522–531.
   PubMed Web of Science ®Google Scholar
• Guo J, Meng F, Ma N, et al. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia. Am J Cardiol. 2012;110:1296–1301.
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120–122.
   PubMed Web of Science ®Google Scholar
• Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008;2:426–435.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Safety considerations with fenofibrate/simvastatin combination. Expert Opin Drug Saf. 2015;14:1481–1493.
   PubMed Web of Science ®Google Scholar
• Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16:352–358.
   PubMed Web of Science ®Google Scholar
• Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol. 2002;89:390–394.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. Jama. 2003;289:1681–1690.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367–383.
   PubMed Web of Science ®Google Scholar
• Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004;279:50630–50638.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–156.
   PubMed Web of Science ®Google Scholar
• Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32:71–77.
   PubMed Web of Science ®Google Scholar
• Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011;216:258–265.
   PubMed Web of Science ®Google Scholar
• Do RQ, Vogel RA, Schwartz GG. PCSK9 Inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep. 2013;15:345.
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Descamps OS, Fraass U, et al. Systematic review of published phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol. 2016. DOI:10.1111/bcp.13066
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016;4:403–410.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Blom D et al. Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for or at low risk for diabetes mellitus. Presented in the European Association for the Study of Diabetes Stockholm, Sweden, 2015, Sept, 17 Session OP 27.
   Google Scholar
• Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(906–15):e13.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Ginsberg HN, Robinson JG, et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J. 2016. doi: 10.1093/eurheartj/ehw292.
   PubMed Web of Science ®Google Scholar
• Achimastos A, Alexandrides T, Alexopoulos D, et al. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones (Athens). 2016;15:8–14.
   PubMedGoogle Scholar
• Kosmas CE, DeJesus E, Rosario D, et al. CETP inhibition: past failures and future hopes. Clin Med Insights Cardiol. 2016;10:37–42.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Klouras E, Barkas F, et al. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Rev Cardiovasc Ther. 2016;14:953–962.
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370:1907–1914.
   PubMed Web of Science ®Google Scholar
• Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(352–60):e2.
   Google Scholar
• Kastelein JJ, Besseling J, Shah S, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385:2153–2161.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415.
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Kastelein JJ, Van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386:452–460.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye KA, Tardif JC, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011;124:555–562.
   PubMed Web of Science ®Google Scholar
• Siebel AL, Natoli AK, Yap FY, et al. Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res. 2013;113:167–175.
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
   PubMed Web of Science ®Google Scholar
• Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9:533–571.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Koulouris S, et al. Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes? Int J Clin Pract. 2010;64:1632–1642.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes. 2007;115:477–482.
   PubMed Web of Science ®Google Scholar
• Ansquer JC, Corda C, Le Malicot K, et al. Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study. Curr Ther Res Clin Exp. 2009;70:71–93.
   PubMed Web of Science ®Google Scholar
• Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb. 2007;14:128–132.
   PubMed Web of Science ®Google Scholar
• Rizos CV, Kostapanos MS, Rizos EC, et al. The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose. J Cardiovasc Pharmacol Ther. 2015;20:276–283.
   PubMed Web of Science ®Google Scholar
• Florentin M, Tselepis AD, Elisaf MS, et al. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol. 2010;8:820–830.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Filippatos TD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther. 2007;29:1403–1414.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Kostapanos MS, Tsimihodimos V, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract. 2012;66:843–853.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Lagos KG, et al. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol. 2008;590:327–332.
   PubMed Web of Science ®Google Scholar
• Ikewaki K, Tohyama J, Nakata Y, et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. J Atheroscler Thromb. 2004;11:278–285.
   PubMedGoogle Scholar
• Winkler K, Schewe T, Putz G, et al. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest. 2009;39:463–470.
   PubMed Web of Science ®Google Scholar
• Nozue T, Hattori H, Ogawa K, et al. Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. Lipids Health Dis. 2016;15:165.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu RX, Li S, et al. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. Nutr Metab Cardiovasc Dis. 2015;25:426–433.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Kereiakes D, Pourfarzib R, et al. Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. J Am Heart Assoc. 2015. doi: 10.1161/JAHA.115.002224
   PubMed Web of Science ®Google Scholar
• Toth PP, Hamon SC, Jones SR, et al. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis. 2016;15:28.
   PubMed Web of Science ®Google Scholar
• Si-Tayeb K, Cariou B. PCSK9 Inhibition: Does Lipoprotein Size Matter?. J Am Heart Assoc. 2015. doi: 10.1161/JAHA.115.002806.
   Web of Science ®Google Scholar
• Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012;53:540–547.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Tomkin GH, Patti AM, et al. Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. Clinical Lipidology. 2011;6:539–547.
   Web of Science ®Google Scholar
• Rizzo M, Vekic J, Koulouris S, et al. Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes. Angiology. 2010;61:584–590.
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes. Expert Opin Pharmacother. 2008;9:343–349.
   PubMed Web of Science ®Google Scholar